Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

Alcon, the global leader in eye care, offers a broad portfolio of products to enhance sight and improve lives for patients in more than 140 countries.

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease“Many of my patients continue to face frustrating ...

Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which ...

Alcon Inc.’s ALC UNITY Vitreoretinal Cataract System (“VCS”) has recently received approval from Health Canada. UNITY VCS is ...

GENEVA& DURHAM, N.C.---- Alcon, the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc., a pharmaceutical company focused on the discovery ...

Alcon AG plans to acquire Lumithera Inc., adding its photobiomodulation (PBM) device designed to treat early and intermediate ...

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal ...

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease ...